Emiliano Calvo, M.D., Ph.D.
Director of START Madrid Group
Emiliano Calvo, M.D., Ph.D., is the Director of START Madrid Group in Madrid, and the Director of Clinical Research at the START Madrid-CIOCC site, in Madrid, Spain. He is also the Director of the Investigational Therapeutics in Oncological Sciences Foundation (Intheos). In addition, he is an Associate Professor at University CEU San Pablo in Madrid, Spain, and Faculty member at the International Workshop in Methods in Clinical Cancer Research, in Flims, Switzerland.
He earned his M.D. in 1993 at the Universidad Autónoma de Madrid in Madrid, Spain and his Ph.D. in 2003 at the Universidad de Navarra in Pamplona, Spain, with highest commendation. He trained in Medical Oncology at the Clínica Universitaria de Navarra in Pamplona, Spain and completed his Advanced Fellowship in Drug Development at the Cancer Therapy & Research Center’s Institute for Drug Development in San Antonio, Texas, from 2003 to 2005, where he was a Senior Fellow and Clinical Investigator.
While working in the Medical Oncology Department at the Hospital Vall d'Hebron in Barcelona, Spain, Dr. Calvo headed the Brain Tumors Area from 2007 until 2008, the Genitourinary Tumor and Sarcoma Area from 2006 until 2008, the Pharmacokinetics Unit from 2005 until 2008, and was Co-Director and Senior Researcher of the Phase I Unit.
Dr. Calvo’s major interests are the early clinical development of novel anticancer drugs, and pharmacokinetics.
Dr. Calvo has co-authored approximately one hundred publications, especially regarding clinical development of new drugs in different tumor types. These publications include scientific articles, chapters in oncology books and communications at different conferences and meetings. He has also participated in approximately 80 clinical trials, more than half of them in Phase I international studies, as an investigator. He serves as an ad-hoc reviewer of various oncology journals, is a Faculty member of the Clinical Trials and Systemic Therapy Group, of the Educational Committee of the European Society of Medical Oncology, and member of the 2008, 2009 and 2011 scientific committees of the annual meetings of the European Society of Medical Oncology. He is also a member of the scientific committee of the ESMO–ECCO (European Cancer Organization) Multidisciplinary Congress for the Drug Development track committee, and the non-prostate genitourinary committee, and is currently a member of the Scientific Program Committee on the Developmental Therapeutics - Clinical Pharmacology & Experimental Track of the Annual Meetings of the American Society of Clinical Oncology (ASCO), and an international member of the peer review panel for the National Cancer Research Institute of Renal Clinical Studies Group of the United Kingdom.
Ana Díez, BCOP
Director of Investigational Pharmacy at START Madrid
Ana Díez is the Director of Investigational Pharmacy at START Madrid. Ana Díez is Hospital Pharmacy Specialist and a Board Certified Oncology Pharmacist.
Ms. Díez Martinez finished her studies in Pharmacy at the Universidad de Valencia, in Valencia, Spain in 2000. She received a grant from the Universidad de Valencia to study new drugs within the Pharmacokinetic Department. She obtained her Diploma de Estudios Avanzados from the School of Medicine at the Universidad Autónoma de Madrid in Madrid, Spain in 2004. In 2005, She completed her residency in Hospital Pharmacy at the Complejo Hospitalario Universitario de Albacete in Albacete, Spain. While at Complejo Hospitalario Universitario de Albacete Díez Martinez became a staff member and served on the Hospital Ethics Committee. She also received a grant from Fundación Española de Farmacia Hospitalaria to continue her studies in Clinical Pharmacy at Yale-New Haven Hospital, in New Haven, Connecticut, USA. In 2006, She joined the Oncology Pharmacy Section at the Hospital San Rafael in Madrid, Spain.
She has been working in the Investigational Pharmacy at the Hospital Universitario Sanchinarro and She has been participating as a member of the Hospital Ethics Committee since 2008.
She has a Masters in Clinical Pharmacy from the Universidad de Valencia and She is a Board Certified Oncology Pharmacist since 2011.
Ms. Díez Martinez has presented more than 30 scientific papers at national and international meetings and she has been a member of the Spanish Society of Hospital Pharmacy since 2001.
Director of Phase I Nursing and Pharmacocinetic Departments
Esther Ordóñez is the Director of Phase I Nursing and Pharmacocinetic Departments at START Madrid.
Ms. Ordóñez is a graduate of the Universidad Autónoma de Madrid - Fundación Jiménez Díaz School of Nursing in Madrid, Spain.Ms. Ordóñez worked in different public and private hospitals in Spain and England, and her oncology experience started at MD Anderson International Spain, where she worked as a Registered Nurse in the Ambulatory Treatment Center for 3 years and as a Nurse Educator Coordinator and Wound Ostomy Continence Nurse for 4 years. Ms. Ordóñez is a member of the Spanish Oncology Nursing Society (SEEO) and the European Oncology Nursing Society (EONS).
Beatriz Tapia, Ph.D
Director of Regulatory Affairs and Data Management Departments
Beatriz Tapia, Ph.D is the Director of Regulatory Affairs and Data Management Departments at START Madrid. In addition, Ms. Tapia is professor of the Master in Clinical Research applied to Oncology of the University CEU San Pablo, Madrid.
Ms. Tapia is a cum laude Doctor in Biochemistry by the School of Medicine at the UniversityAutónoma in Madrid, Spain; with a Masters degree in Clinical and Pharmaceutical Research.
Ms. Tapia managed molecular biology research studies at the CSIC Instituto de Investigaciones Biomedicas, in Madrid where she served for one year, and at the Research Unit of the Universitary Hospital La Paz, Madrid where she served for five years.
Ms. Tapia has worked as a Clinical Research Associate at Lilly and Wyeth Laboratories mainly in their Oncology Phase I and II clinical trials for five years. Among her responsibilities Ms. Tapia participated in the selection of suitable sites for clinical trials, submission to IEC and regulatory authorities, performed site initiation visits providing training to investigator staff on the study protocol, and performed monitoring visits following the progress of the clinical trial at each site.